FDA Grants Orphan Drug Designation to Gene Therapy Treatment for Angelman Syndrome
Agilis Biotherapeutics and Dr. Edwin Weeber take giant step forward toward a functional cure for Angelman Syndrome. For Further information, read the press release here.
